Literature DB >> 24029696

Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography.

Ivana Mikolasevic1, Sanjin Racki, Ivan Bubic, Ita Jelic, Davor Stimac, Lidija Orlic.   

Abstract

BACKGROUND/AIM: Preliminary data suggest an association between chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD). The aim of this study was to further investigate the association between NAFLD and decreased kidney function.
METHODS: A total of 62 patients with CKD were enrolled in the study. Liver stiffness was used to detect liver fibrosis and CAP (controlled attenuation parameter) was used to detect and quantify liver steatosis (Fibroscan®). NAFLD was defined by CAP values ≥238 dB.m(-1).
RESULTS: CKD stage III was present in 29 patients (46.8%) and CKD stage IV in 33 patients (53.2%). Out of 62 CKD patients 53 (85.5%) had NAFLD and of these 14/53 patients (26.4%) had also liver stiffness >7 kPa. The severity of liver steatosis was positively correlated with serum creatinine (r=0.399;p<0.01) and CRP (r=0.261; p<0.05) and negatively correlated with eGFR (r=-0.413; p<0.01) and serum iron concentration (r=-0.365; p<0.01).
CONCLUSION: The results suggest a high prevalence of NAFLD in CKD patients. The severity of liver steatosis is negatively correlated with kidney function. The study documents the value of ultrasonographic elastography as an effective non-invasive screening method for the diagnosis of NAFLD.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24029696     DOI: 10.1159/000350158

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  27 in total

1.  Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.

Authors:  Ivana Mikolasevic; Sandra Milic; Sanjin Racki; Luka Zaputovic; Davor Stimac; Mladen Radic; Dean Markic; Lidija Orlic
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

2.  Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Luka Zaputovic; Sanjin Racki; Zlatko Cubranic; Kata Anic; Bosiljka Devcic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

3.  Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity.

Authors:  John D Clarke; Anika Dzierlenga; Tarana Arman; Erica Toth; Hui Li; Katherine D Lynch; Dan-Dan Tian; Michael Goedken; Mary F Paine; Nathan Cherrington
Journal:  Toxicon       Date:  2019-03-05       Impact factor: 3.033

4.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

Review 5.  Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Pharmacol Ther       Date:  2015-03-21       Impact factor: 12.310

6.  Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.

Authors:  Lidija Orlic; Ivana Mikolasevic; Vesna Lukenda; Kata Anic; Ita Jelic; Sanjin Racki
Journal:  Wien Klin Wochenschr       Date:  2014-11-21       Impact factor: 1.704

7.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

8.  Transient elastography: a new noninvasive diagnostic tool for assessment of chronic allograft nephropathy.

Authors:  V Lukenda; I Mikolasevic; S Racki; I Jelic; D Stimac; L Orlic
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

Review 9.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

10.  Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography.

Authors:  Maha Abdelmoneim Behairy; Ahmed Fouad Sherief; Hany Aly Hussein
Journal:  Int Urol Nephrol       Date:  2021-03-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.